BioPharma Resources

Drug Trial Radar · NCT04547166

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

A Randomized, Double-blind, Multicenter, PhaseⅡ/Ⅲ Clinical Study of Serplulimab in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC)

Last checked: Nov 19, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 568 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

568

Planned (sponsor's estimate)

Start

Mar 10, 2021

Primary completion

Sep 24, 2025

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Sep 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of Serplulimab (HLX10) in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC)

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • HLX10Drug

    a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.

  • HLX04、Drug

    7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Linyi Cancer Hospital

    Linyi, China · Recruiting

  • Fudan University Affiliated Oncology Hospital

    Shanghai, China · Recruiting

  • Center for Cancer Prevention and Treatment of Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • National Cancer Center

    Kashiwa, Japan · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.